References
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med [Internet]. 2011;364(11):1046–1060. Available from http://www.ncbi.nlm.nih.gov/pubmed/21410373
- Myeloma - SEER stat fact sheets [internet]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html.
- Lonial S. Treatment of MM: upcoming novel therapies [Internet]. Cancer Treat Res. 2016;169:195–205. Available from http://www.ncbi.nlm.nih.gov/pubmed/27696264
- Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood [Internet]. 2012;119(19):4375–4382. Available from http://www.ncbi.nlm.nih.gov/pubmed/22422823
- Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood [Internet]. 2010;116(5):679–686. Available from http://www.ncbi.nlm.nih.gov/pubmed/20385792
- Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood [Internet]. 2008;111(5):2516–2520. Available from http://www.ncbi.nlm.nih.gov/pubmed/17975015
- Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leuk [Internet]. 2012;26(1):149–157. Available from http://www.ncbi.nlm.nih.gov/pubmed/21799510
- Dingli D, Rajkumar SV. How best to use new therapies in multiple myeloma. Blood Rev [Internet]. 2010;24(3):91–100. Available from http://www.ncbi.nlm.nih.gov/pubmed/20359801
- Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol [Internet]. 2016;9(1):52. Available from http://www.ncbi.nlm.nih.gov/pubmed/27363832
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. Available from http://www.ncbi.nlm.nih.gov/pubmed/25439696
- Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med [Internet]. 2007;356:2582–2590. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17582068
- Pérez-Persona E, Vidriales M-B, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood [Internet]. 2007;110:2586–2592. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17576818
- Pérez-Persona E, Mateo G, García-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol Internet. 2010;148:110–114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19821821
- Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood Internet. 2008;111:785–789. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17942755
- Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med Internet. 2013;369(5):438–447. Available from http://www.ncbi.nlm.nih.gov/pubmed/23902483
- Mateos M-V, Hernandez MT, Giraldo P, et al. Long term follow-up on the tretament of high risk smoldering myeloma with lenalidomide plus low dose dex (Rd) (phase III spanish trial): persistent benefit in overall survival. Blood. 2014;124(21) abstract 3465.
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol [Internet]. 2003;121(5):749–757. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12780789
- Mateos M-V, San Miguel J-F. Smoldering multiple myeloma: when to observe and when to treat? Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet [Internet]. 2015;35:e484–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25993213
- Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol [Internet]. 2011;8(8):479–491. Available from http://www.ncbi.nlm.nih.gov/pubmed/21522124
- Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood [Internet]. 2015;125(13):2068–2074. Available from http://www.ncbi.nlm.nih.gov/pubmed/25628469
- Larocca A, Palumbo A. How I treat fragile myeloma patients. Blood [Internet]. 2015;126(19):2179–2185. Available from http://www.ncbi.nlm.nih.gov/pubmed/26324701
- Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica [Internet]. 2016;101(9):1110–1119. Available from http://www.ncbi.nlm.nih.gov/pubmed/27479825
- Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc [Internet]. 2013;88(4):360–376. Available from http://www.ncbi.nlm.nih.gov/pubmed/23541011
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol [Internet]. 2015;33(26):2863–2869. Available from http://www.ncbi.nlm.nih.gov/pubmed/26240224
- Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol [Internet]. 2016;91(7):719–734. Available from http://www.ncbi.nlm.nih.gov/pubmed/27291302
- Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91–97.
- Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–1883.
- Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med [Internet]. 2014;371(10):895–905. Available from http://www.ncbi.nlm.nih.gov/pubmed/25184862
- Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629.
- Cavo M, Beksac M, Dimopoulos MA, et al. Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the european myeloma network (EMN02/HO95 MM Trial). Blood. 2016;128(22) abstract 673.
- Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the intergroupe francophone du myelome (IFM/DFCI 2009 trial). Blood. 2015;126(23):391–391.
- Hanaizi Z, Flores B, Hemmings R, et al. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist [Internet]. 2015;20(3):329–334. Available from http://www.ncbi.nlm.nih.gov/pubmed/25673103
- Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leuk [Internet]. 2014;28(8):1573–1585. Available from http://www.ncbi.nlm.nih.gov/pubmed/24496300
- Elkinson S, McCormack PL. Pomalidomide: first global approval. Drugs [Internet]. 2013;73(6):595–604. Available from http://www.ncbi.nlm.nih.gov/pubmed/23572409
- Dimopoulos MA, Sonneveld P, Siegel D, et al. Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2015;26(11):2247–2256. Available from http://www.ncbi.nlm.nih.gov/pubmed/26216385
- San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol [Internet]. 2013;14(11):1055–1066. Available from http://www.ncbi.nlm.nih.gov/pubmed/24007748
- Dimopoulos MA, Weisel KC, Song KW, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica [Internet]. 2015;100(10):1327–1333. Available from http://www.ncbi.nlm.nih.gov/pubmed/26250580
- San Miguel JF, Weisel KC, Song KW, et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica [Internet]. 2015;100(10):1334–1339. Available from http://www.ncbi.nlm.nih.gov/pubmed/26160879
- Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUSTM (MM-010): a phase 3b study in refractory multiple myeloma. Blood [Internet]. 2016;128:497–503. Available from http://www.ncbi.nlm.nih.gov/pubmed/27226434
- Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood [Internet]. 2013;122(16):2799–2806. Available from http://www.ncbi.nlm.nih.gov/pubmed/23954889
- Baz RC, Martin TG, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood [Internet]. 2016;127(21):2561–2568. Available from http://www.ncbi.nlm.nih.gov/pubmed/26932802
- Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood [Internet]. 2015;126(20):2284–2290. Available from http://www.ncbi.nlm.nih.gov/pubmed/26384354
- Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood [Internet]. 2012;120(14):2817–2825. Available from http://www.ncbi.nlm.nih.gov/pubmed/22833546
- Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med [Internet]. 2015;372(2):142–152. Available from HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed/25482145” http://www.ncbi.nlm.nih.gov/pubmed/25482145
- Raedler LA. Kyprolis (Carfilzomib) received new indications as combination therapy for use in relapsed and/or refractory multiple myeloma. Am Heal Drug Benefits [Internet]. 2016;9(Spec Feature):93–96. Available from http://www.ncbi.nlm.nih.gov/pubmed/27668053
- Perel G, Bliss J, Thomas CM. Carfilzomib (Kyprolis): a novel proteasome inhibitor for relapsed and/or refractory multiple myeloma. P T [Internet]. 2016;41(5):303–307. Available from http://www.ncbi.nlm.nih.gov/pubmed/27162470
- Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
- Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood [Internet]. 2016;127(26):3360–3368. Available from http://www.ncbi.nlm.nih.gov/pubmed/27207788
- Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood [Internet]. 2014;124(1):63–69. Available from http://www.ncbi.nlm.nih.gov/pubmed/24855212
- Moreau P, Kolb B, Attal M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood [Internet]. 2015;125(20):3100–3104. Available from http://www.ncbi.nlm.nih.gov/pubmed/25784682
- Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med [Internet]. 2016;374(17):1621–1634. Available from http://www.ncbi.nlm.nih.gov/pubmed/27119237
- Richardson PG, Zimmerman TM, Hofmeister CC, et al. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood [Internet]. 2016;127(22):2693–2700. Available from http://www.ncbi.nlm.nih.gov/pubmed/27009059
- Harrison SJ, Mainwaring P, Price T, et al. Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results. Clin Cancer Res [Internet]. 2016;22(18):4559–4566. Available from http://www.ncbi.nlm.nih.gov/pubmed/27117181
- Vij R, Savona M, Siegel DS, et al. Clinical profile of single-agent oprozomib in Patients (Pts) with Multiple Myeloma (MM): updated results from a multicenter, open-label, dose escalation Phase 1b/2 Study. Blood. 2014;124(21) abstract 34.
- Palumbo A, Sonneveld P. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. Expert Rev Hematol [Internet]. 2015;8(4):481–491. Available from http://www.ncbi.nlm.nih.gov/pubmed/26070331
- Raedler LA. Empliciti (Elotuzumab): first SLAMF7 antibody therapy approved for the treatment of patients with previously treated multiple myeloma. Am Heal Drug Benefits [Internet]. 2016;9(Spec Feature):74–77. Available from http://www.ncbi.nlm.nih.gov/pubmed/27668048
- Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med [Internet]. 2015;373(7):621–631. Available from http://www.ncbi.nlm.nih.gov/pubmed/26035255
- Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myeloma. Blood [Internet]. 2016;127:2833–2840. Available from http://www.ncbi.nlm.nih.gov/pubmed/27091875
- McKeage K. Daratumumab: first global approval. Drugs [Internet]. 2016;76(2):275–281. Available from http://www.ncbi.nlm.nih.gov/pubmed/26729183
- Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med [Internet]. 2015;373(13):1207–1219. Available from http://www.ncbi.nlm.nih.gov/pubmed/26308596
- Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet (London, England) [Internet]. 2016;387(10027):1551–1560. Available from http://www.ncbi.nlm.nih.gov/pubmed/26778538
- Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood [Internet]. 2016;128(1):37–44. Available from http://www.ncbi.nlm.nih.gov/pubmed/27216216
- Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med [Internet]. 2016;375(8):754–766. Available from http://www.ncbi.nlm.nih.gov/pubmed/27557302
- Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med [Internet]. 2016;375(14):1319–1331. Available from http://www.ncbi.nlm.nih.gov/pubmed/27705267
- Attal M, Palumbo A, Holstein SA, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). 2016 ASCO Annual Meeting |Abstracts |Meeting Library [Internet]. In: ASCO., 34: abstr 8001 (2016). Available from: http://meetinglibrary.asco.org/content/168948-176.
- Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–1544.
- Yousef S, Marvin J, Steinbach M, et al. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J. 2015;5(3):e285.
- Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704.
- San Miguel J, Mateos M-V, Shah JJ, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): keynote-023. Blood. 2015;126(23) abstract 505.
- Gorgun G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607–4618.
- Badros AZ, Hyjek E, Ma N, et al. Pembrolizumab in combination with pomalidomide and dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2016;128(22) abstract 490.
- Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun [Internet]. 2014;5:2997. Available from http://www.ncbi.nlm.nih.gov/pubmed/24429703
- Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067–1076.
- Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood [Internet]. 2011;118(17):4519–4529. Available from http://www.ncbi.nlm.nih.gov/pubmed/21841166
- Paiva B, Vidriales M-B, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood [Internet]. 2008;112(10):4017–4023. Available from http://www.ncbi.nlm.nih.gov/pubmed/18669875
- Paiva B, Martinez-Lopez J, Vidriales M-B, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol [Internet]. 2011;29(12):1627–1633. Available from http://www.ncbi.nlm.nih.gov/pubmed/21402611
- Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol [Internet]. 2016;17(8):e328–46. Available from http://www.ncbi.nlm.nih.gov/pubmed/27511158